Your blood test says 'normal.' But is it optimal for APOE4?

Standard reference ranges are built from the 95th percentile of the general population, so as overall health declines, the ranges drift with it. A value considered pre-diabetic in 1995 would register as normal today, not because people got healthier but because the reference band shifted. APOE4 carriers are not the general population and cannot afford average when trying to prevent what is written in their genes. Finding APOE4-specific optimal ranges is nearly impossible unless a doctor specializes in APOE4, which most do not.

The analyzer maps your biomarkers against APOE4-specific optimal ranges rather than generic normal bands. It covers ApoB, LDL-C, and cardiovascular lipids alongside advanced Alzheimer biomarkers including plasma pTau-217, the Abeta 42/40 ratio, and GFAP. These advanced markers are predictive of future Alzheimer pathology and increasingly available through specialty labs. The tool then generates personalized intervention protocols with specific actions to move each biomarker from where it is toward the APOE4 target.

The tracker holds 121 supplements filtered by indication and surfaces crowd-sourced data from Phoenix members: average efficacy scores, side effect ratings by brand, typical dosages members take, and what similar carriers with matching profiles are using. You might see that Brand A of omega-3 rates 4.2 out of 5 while Brand B sits at 2.8, or that members similar to you take 2000 mg of resveratrol rather than 500 mg. The goal is to replace guessing and podcast-driven choices with real APOE4-carrier data.

Phoenix partners with pharmaceutical companies and medtech manufacturers to give members early access to breakthrough therapies. Members can browse active partnerships, register interest, and get notified when trial spots open. Automated matching will eventually flag trials members are eligible for based on biomarkers and profile. Phoenix also negotiates group discounts on cutting-edge devices in exchange for anonymized efficacy data sharing, so members receive devices at cost price while companies gain real-world evidence from APOE4 carriers.

Phoenix is launching a device trial focused on auricular vagus nerve stimulation, following the earlier Neuronic photobiomodulation helmet study. Early research suggests vagus nerve stimulation improves sleep quality and reduces stress, two levers that influence APOE4 risk through cortisol, inflammation, and glymphatic clearance. The study follows the same group-discount structure, where members contribute anonymized outcome data and receive the device at cost, generating real-world evidence on what works for APOE4 carriers.